Delphia Trial

Dementia with Lewy Bodies (DLB) is a progressive type of dementia that affects over 1 million people in the United States. DLB is characterized by abnormal buildup of abnormal protein clusters (known as Lewy Bodies) in the brain. People with DLB have fluctuations in cognition, particularly in alertness and attention. Many people with DLB can have visual hallucinations and REM sleep disturbance disorders.

Currently, there are no approved treatments for Lewy Bodies dementia in the United States or Europe.

About the Delphia Trial:

The Delphia study will test an investigational medication to see if it might improve cognitive function including attention, memory, and language in patients who have Dementia with Lewy Bodies.

Who Is Eligible to Participate?

Patients may qualify for this study if they:

  • Are age 50-85
  • Have probable DLB
  • Have no neurological condition contributing to cognitive impairment beyond those caused by DLB
  • Have a study partner who can provide information about the patient throughout the study. This person will attend all study visits with the study participant.

To see if you may qualify, please call us at the number listed above in the top right corner of the page, or fill out the form to the right and we will contact you.

Related Research Studies


Condition We Study
shadow
Alzheimer’s disease is a progressive, degenerative disease that destroys nerve cells (neurons) in the brain.
Condition We Study
shadow
Early Memory Loss is a condition marked by memory loss that is annoying and frustrating to the person experiencing it, but does not significantly affect a person’s ability to function.